Speaking at the World Health Organization's executive board meeting on October 6, the agency's Director-General Tedros Adhanom Ghebreyesus said "there is hope" that a vaccine against COVID-19 may be ready by the end of this year. During his closing remarks, Tedros called for solidarity an...
"So we do need more vaccines to come to the market. The vaccines need to be emergency use by WHO in order for them to be used for international procurement." Hungarian Prime Minister Viktor Orban is seen receiving a dose of Sinopharm's COVID-19 vaccine in a video released o...
Omicron: 'Too late' to use border controls The incoming chancellor is likely to continue Austria's current COVID-19 measures, which are among the most restrictive in Europe, including a full lockdown and a pending vaccine mandate. Individual freedom needs to end where the freedom of others...
Answering questions about vaccine development, WHO's chief scientist Dr. Soumya Swaminathan said both the U.S. and China have been running clinical trials on human bodies but a vaccine is still at least 12 to 18 months away.RELATED STORIES Altadena resident who lost home shares E...
Good morning, good afternoon and good evening.Yesterday, 230,000 cases of COVID-19 were reported to WHO.Almost 80% of those cases were reported from just 10 countries, and 50% come from just two countries.Although the number of daily deaths remains relatively stable, there is a lot to b...
"There is an opportunity to strengthen partnerships to transfer vaccine manufacturing technology, whether between the developed countries and the six countries, or among the six countries themselves," she said, stressing that the WHO will play a fundamental role in supporting the pharmaceutical industrie...
GENEVA, May 19 (Xinhua) -- The World Health Organization (WHO) validated on Thursday the CONVIDECIA COVID-19 vaccine developed by Chinese developer CanSino Biologics for emergency use, making it the third Chinese vaccine after Sinopharm and Sinovac having been certified by WHO Emergency Use ...
CONVIDECIA, administered as a single dose, "is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2," the virus behind COVID-19. The vaccine was found to have 64 percent efficacy against symptomatic disease and 92 percent against severe COVID-19. ...
CONVIDECIA, administered as a single dose, “is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2,“ the virus behind COVID-19. The vaccine was found to have 64 percent efficacy against symptomatic disease and 92 percent against severe COVID-19. ...
“He was there about six days and then finally they said he’s not going to make it," Charnese Davis recalled. MORE: More businesses are mandating COVID-19 vaccines. Is that legal? Despite initially being hesitant to take the vaccine, Marquis Davis told his wife he wanted to...